Company intelligence / Profile preview

SignaBlok, Inc.

Shrewsbury, Massachusetts, United Statessignablok.com ↗

Ownership: Private
Development stage: Preclinical

Overview

SignaBlok’s lead program is a macrophage-restricted TREM‑1 inhibitor peptide therapy. In preclinical models of pancreatic cancer, this drug prevented recurrence, improved complete response rate and survival when administered after standard chemotherapy, reversed immunosuppression, overcame resistance to anti-PD-L1 immunotherapy, and was shown to be safe and well-tolerated in rodents. The SCHOOL technology platform underpins these programs with a novel mechanism of action.

Therapeutic areas: OncologyImmunologyCardiovascularInfectious Diseases
Modalities: Peptides (SCHOOL peptides)Nanoparticles/nanosystemsSmall moleculesRNAs
Industry: Biotech

Drug pipeline

2 assets

GF9

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on SignaBlok, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SignaBlok, Inc..

Explore the full profile